RNA Stock Atrium Therapeutics, Inc.
BUY US · NasdaqGSStrong platform story and event-driven biotech appetite support constructive upside.
Future value: $23.00 (+185.71%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Momentum and pipeline catalyst potential remain favorable.
- ▾Below 50-day MA (-20.78%)
- ▾Near 52-week low (6% of range)
- ▸~186% upside to price target
Is RNA a buy right now?
Trend: RNA is trading below the 50-day average (-20.77%), RSI 46 — neutral momentum, with a 3-month return of -29.94%.
Valuation & quality: Atrium Therapeutics, Inc. trades on forward P/E -1.4, price-to-book 0.64; fundamentals show net margin -184.1%, revenue growth -21.9% year on year.
Analyst consensus: 5 analysts have a mean 12-month price target of $23.00 (+185.7% vs the last close; range $15.00 – $25.00), consensus rating “strong buy”.
Our screen: BUY (score 2) — Strong platform story and event-driven biotech appetite support constructive upside.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -9.40% | -4.50% | +1.80% | +3.50% | -15.60% | +17.40% | -37.80% | -2.80% |
Fundamentals
Analyst price target
Technical signals
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies.
Sector: Healthcare · Industry: Biotechnology · United States · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.